Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Harrington Investments INC

Harrington Investments INC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,802 shares of the biopharmaceutical company’s stock after selling 1,575 shares during the quarter. Harrington Investments INC’s holdings in Gilead Sciences were worth $1,829,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Poinciana Advisors Group LLC bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $297,000. Greatmark Investment Partners Inc. lifted its position in shares of Gilead Sciences by 1.9% during the 4th quarter. Greatmark Investment Partners Inc. now owns 33,032 shares of the biopharmaceutical company’s stock valued at $3,051,000 after acquiring an additional 620 shares during the last quarter. Postrock Partners LLC purchased a new position in Gilead Sciences in the 4th quarter worth about $248,000. Wellington Shields Capital Management LLC raised its holdings in shares of Gilead Sciences by 3,757.7% during the fourth quarter. Wellington Shields Capital Management LLC now owns 234,507 shares of the biopharmaceutical company’s stock valued at $21,661,000 after acquiring an additional 228,428 shares during the period. Finally, Atala Financial Inc acquired a new stake in shares of Gilead Sciences in the fourth quarter worth $188,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Price Performance

Shares of GILD stock opened at $111.44 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The business’s 50 day moving average price is $101.82 and its 200-day moving average price is $92.71. The firm has a market cap of $138.78 billion, a P/E ratio of 301.19, a P/E/G ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.84%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on GILD shares. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a research note on Thursday, February 13th. Morgan Stanley upped their price objective on shares of Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research report on Tuesday. Royal Bank of Canada boosted their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a report on Wednesday, February 12th. Finally, Oppenheimer raised their target price on Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 4th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $104.52.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders have sold 311,285 shares of company stock valued at $31,284,910. Insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.